Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-HHLA2 monoclonal antibody NPX887

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against HERV-H LTR-associating protein 2 (HHLA2; HHLA-2; B7 homolog 7; B7-H7), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-HHLA2 monoclonal antibody NPX887 targets and binds to HHLA2, and blocks the interaction between HHLA2 and its receptors. This abrogates the HHLA2-mediated inhibition of T-cell and nature killer (NK) cell activation, which may lead to enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response and NK cell cytotoxicity against cancer cells. HHLA2, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and a negative regulator of T-cell and NK cell activation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-B7-H7 monoclonal antibody NPX887
anti-HHLA-2 monoclonal antibody NPX887
Code name:NPX 887
NPX-887
NPX887
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search